View Future GrowthMabion 過去の業績過去 基準チェック /06Mabionの収益は年間平均-18.5%の割合で減少していますが、 Biotechs業界の収益は年間 増加しています。収益は年間13.4% 3.3%割合で 減少しています。主要情報-18.46%収益成長率-16.42%EPS成長率Biotechs 業界の成長-14.59%収益成長率-3.28%株主資本利益率-146.07%ネット・マージン-324.19%次回の業績アップデート15 Sep 2026最近の業績更新Reported Earnings • May 24First quarter 2026 earnings released: zł0.60 loss per share (vs zł0.94 loss in 1Q 2025)First quarter 2026 results: zł0.60 loss per share (improved from zł0.94 loss in 1Q 2025). Revenue: zł4.57m (up 68% from 1Q 2025). Net loss: zł9.74m (loss narrowed 36% from 1Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 81 percentage points per year, which is a significant difference in performance.お知らせ • Aug 25Mabion S.A. to Report First Half, 2025 Results on Sep 30, 2025Mabion S.A. announced that they will report first half, 2025 results on Sep 30, 2025Reported Earnings • Oct 29Third quarter 2024 earnings released: zł1.01 loss per share (vs zł0.67 profit in 3Q 2023)Third quarter 2024 results: zł1.01 loss per share (down from zł0.67 profit in 3Q 2023). Revenue: zł516.0k (down 98% from 3Q 2023). Net loss: zł16.3m (down 250% from profit in 3Q 2023). Revenue is expected to decline by 11% p.a. on average during the next 3 years, while revenues in the Biotechs industry in Europe are expected to grow by 21%. Over the last 3 years on average, earnings per share has increased by 43% per year but the company’s share price has fallen by 42% per year, which means it is significantly lagging earnings.Reported Earnings • Sep 11Second quarter 2024 earnings releasedSecond quarter 2024 results: Revenue: zł29.8m (down 17% from 2Q 2023). Net income: zł10.3m (down 33% from 2Q 2023). Profit margin: 35% (down from 42% in 2Q 2023). Revenue is expected to decline by 4.2% p.a. on average during the next 3 years, while revenues in the Biotechs industry in Europe are expected to grow by 20%. Over the last 3 years on average, earnings per share has increased by 85% per year but the company’s share price has fallen by 35% per year, which means it is significantly lagging earnings.Reported Earnings • May 19First quarter 2024 earnings released: EPS: zł1.06 (vs zł1.02 in 1Q 2023)First quarter 2024 results: EPS: zł1.06 (up from zł1.02 in 1Q 2023). Revenue: zł34.0m (down 14% from 1Q 2023). Net income: zł17.5m (up 6.5% from 1Q 2023). Profit margin: 52% (up from 42% in 1Q 2023). Revenue is forecast to grow 4.4% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has increased by 91% per year but the company’s share price has fallen by 27% per year, which means it is significantly lagging earnings.Reported Earnings • Apr 18Full year 2023 earnings released: EPS: zł2.55 (vs zł1.44 in FY 2022)Full year 2023 results: EPS: zł2.55 (up from zł1.44 in FY 2022). Revenue: zł151.7m (down 7.5% from FY 2022). Net income: zł41.3m (up 78% from FY 2022). Profit margin: 27% (up from 14% in FY 2022). The increase in margin was driven by lower expenses. Revenue is expected to decline by 1.1% p.a. on average during the next 3 years, while revenues in the Biotechs industry in Europe are expected to grow by 18%. Over the last 3 years on average, earnings per share has increased by 103% per year but the company’s share price has fallen by 36% per year, which means it is significantly lagging earnings.すべての更新を表示Recent updatesReported Earnings • May 24First quarter 2026 earnings released: zł0.60 loss per share (vs zł0.94 loss in 1Q 2025)First quarter 2026 results: zł0.60 loss per share (improved from zł0.94 loss in 1Q 2025). Revenue: zł4.57m (up 68% from 1Q 2025). Net loss: zł9.74m (loss narrowed 36% from 1Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 81 percentage points per year, which is a significant difference in performance.お知らせ • Aug 25Mabion S.A. to Report First Half, 2025 Results on Sep 30, 2025Mabion S.A. announced that they will report first half, 2025 results on Sep 30, 2025お知らせ • Apr 25Mabion S.A., Annual General Meeting, May 26, 2025Mabion S.A., Annual General Meeting, May 26, 2025.Valuation Update With 7 Day Price Move • Nov 05Investor sentiment deteriorates as stock falls 27%After last week's 27% share price decline to €2.55, the stock trades at a trailing P/E ratio of 18.9x. Average trailing P/E is 24x in the Biotechs industry in Europe. Total loss to shareholders of 84% over the past three years.Reported Earnings • Oct 29Third quarter 2024 earnings released: zł1.01 loss per share (vs zł0.67 profit in 3Q 2023)Third quarter 2024 results: zł1.01 loss per share (down from zł0.67 profit in 3Q 2023). Revenue: zł516.0k (down 98% from 3Q 2023). Net loss: zł16.3m (down 250% from profit in 3Q 2023). Revenue is expected to decline by 11% p.a. on average during the next 3 years, while revenues in the Biotechs industry in Europe are expected to grow by 21%. Over the last 3 years on average, earnings per share has increased by 43% per year but the company’s share price has fallen by 42% per year, which means it is significantly lagging earnings.Reported Earnings • Sep 11Second quarter 2024 earnings releasedSecond quarter 2024 results: Revenue: zł29.8m (down 17% from 2Q 2023). Net income: zł10.3m (down 33% from 2Q 2023). Profit margin: 35% (down from 42% in 2Q 2023). Revenue is expected to decline by 4.2% p.a. on average during the next 3 years, while revenues in the Biotechs industry in Europe are expected to grow by 20%. Over the last 3 years on average, earnings per share has increased by 85% per year but the company’s share price has fallen by 35% per year, which means it is significantly lagging earnings.New Risk • Sep 03New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 100% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 100% per year for the foreseeable future. High level of non-cash earnings (128% accrual ratio). Minor Risk Market cap is less than US$100m (€71.8m market cap, or US$79.2m).New Risk • Jul 16New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 112% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 112% per year for the foreseeable future. High level of non-cash earnings (128% accrual ratio). Minor Risk Market cap is less than US$100m (€66.5m market cap, or US$72.4m).お知らせ • May 25Mabion S.A., Annual General Meeting, Jun 17, 2024Mabion S.A., Annual General Meeting, Jun 17, 2024.Reported Earnings • May 19First quarter 2024 earnings released: EPS: zł1.06 (vs zł1.02 in 1Q 2023)First quarter 2024 results: EPS: zł1.06 (up from zł1.02 in 1Q 2023). Revenue: zł34.0m (down 14% from 1Q 2023). Net income: zł17.5m (up 6.5% from 1Q 2023). Profit margin: 52% (up from 42% in 1Q 2023). Revenue is forecast to grow 4.4% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has increased by 91% per year but the company’s share price has fallen by 27% per year, which means it is significantly lagging earnings.Valuation Update With 7 Day Price Move • May 14Investor sentiment improves as stock rises 15%After last week's 15% share price gain to €4.28, the stock trades at a trailing P/E ratio of 7.1x. Average trailing P/E is 31x in the Biotechs industry in Europe. Total loss to shareholders of 57% over the past three years.Reported Earnings • Apr 18Full year 2023 earnings released: EPS: zł2.55 (vs zł1.44 in FY 2022)Full year 2023 results: EPS: zł2.55 (up from zł1.44 in FY 2022). Revenue: zł151.7m (down 7.5% from FY 2022). Net income: zł41.3m (up 78% from FY 2022). Profit margin: 27% (up from 14% in FY 2022). The increase in margin was driven by lower expenses. Revenue is expected to decline by 1.1% p.a. on average during the next 3 years, while revenues in the Biotechs industry in Europe are expected to grow by 18%. Over the last 3 years on average, earnings per share has increased by 103% per year but the company’s share price has fallen by 36% per year, which means it is significantly lagging earnings.お知らせ • Jan 12+ 3 more updatesMabion S.A. to Report Q3, 2024 Results on Nov 25, 2024Mabion S.A. announced that they will report Q3, 2024 results on Nov 25, 2024New Risk • Dec 04New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 8.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 28% per year for the foreseeable future. High level of non-cash earnings (34% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (8.3% average weekly change). Market cap is less than US$100m (€84.4m market cap, or US$91.3m).Valuation Update With 7 Day Price Move • Nov 29Investor sentiment improves as stock rises 22%After last week's 22% share price gain to €4.80, the stock trades at a forward P/E ratio of 17x. Average forward P/E is 25x in the Biotechs industry in Europe. Total returns to shareholders of 7.0% over the past year.New Risk • Nov 17New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 34% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 18% per year for the foreseeable future. High level of non-cash earnings (34% accrual ratio). Minor Risk Market cap is less than US$100m (€65.7m market cap, or US$71.2m).Reported Earnings • Sep 14Second quarter 2023 earnings releasedSecond quarter 2023 results: Revenue: zł36.0m (down 18% from 2Q 2022). Net income: zł15.2m (up 198% from 2Q 2022). Profit margin: 42% (up from 12% in 2Q 2022). The increase in margin was driven by lower expenses. Revenue is forecast to grow 7.4% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in Germany.お知らせ • Jun 13Mabion S.A., Annual General Meeting, Jun 13, 2023Mabion S.A., Annual General Meeting, Jun 13, 2023, at 14:00 Central European Standard Time.お知らせ • Jan 26+ 3 more updatesMabion S.A. to Report Fiscal Year 2022 Results on Apr 25, 2023Mabion S.A. announced that they will report fiscal year 2022 results at 5:30 PM, Central European Standard Time on Apr 25, 2023Valuation Update With 7 Day Price Move • Aug 11Investor sentiment deteriorated over the past weekAfter last week's 21% share price decline to €5.64, the stock trades at a trailing P/E ratio of 16.1x. Average forward P/E is 25x in the Biotechs industry in Europe. Total loss to shareholders of 62% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €2.51 per share.Valuation Update With 7 Day Price Move • Jul 18Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to €6.22, the stock trades at a trailing P/E ratio of 18.2x. Average forward P/E is 30x in the Biotechs industry in Europe. Total loss to shareholders of 50% over the past year.Valuation Update With 7 Day Price Move • Jul 02Investor sentiment improved over the past weekAfter last week's 16% share price gain to €5.28, the stock trades at a trailing P/E ratio of 15x. Average forward P/E is 32x in the Biotechs industry in Europe. Total loss to shareholders of 64% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €2.41 per share.Valuation Update With 7 Day Price Move • Jun 15Investor sentiment deteriorated over the past weekAfter last week's 27% share price decline to €4.51, the stock trades at a trailing P/E ratio of 12.7x. Average forward P/E is 31x in the Biotechs industry in Europe. Total loss to shareholders of 74% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €2.47 per share.お知らせ • May 27Mabion S.A., Annual General Meeting, Jun 21, 2022Mabion S.A., Annual General Meeting, Jun 21, 2022, at 11:00 Central European Standard Time.Breakeven Date Change • Apr 27Forecast breakeven date moved forward to 2022The analyst covering Mabion previously expected the company to break even in 2023. New forecast suggests the company will make a profit of zł59.0m in 2022. Average annual earnings growth of 69% is required to achieve expected profit on schedule.Breakeven Date Change • Jul 27Forecast breakeven moved forward to 2022The 2 analysts covering Mabion previously expected the company to break even in 2023. New consensus forecast suggests the company will make a profit of zł59.0m in 2022. Average annual earnings growth of 63% is required to achieve expected profit on schedule.収支内訳Mabion の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史DB:272 収益、費用、利益 ( )PLN Millions日付収益収益G+A経費研究開発費31 Mar 2618-5732031 Dec 2516-6334030 Sep 2515-5924030 Jun 2511-6532031 Mar 2538-3938031 Dec 2469-642130 Sep 241111053230 Jun 241403749331 Mar 241464242531 Dec 231524140630 Sep 231485839830 Jun 2315742351431 Mar 2316532311531 Dec 2216423291530 Sep 221564534830 Jun 221173434931 Mar 22752632831 Dec 21362301430 Sep 212-51212830 Jun 212-45202431 Mar 210-53203031 Dec 200-56193430 Sep 200-55173630 Jun 200-63184031 Mar 200-69214331 Dec 190-64214130 Sep 190-65224030 Jun 190-59213931 Mar 190-70204531 Dec 180-69204530 Sep 180-72234830 Jun 180-74234931 Mar 180-59224131 Dec 170-58214330 Sep 170-56184330 Jun 170-57164731 Mar 170-59154731 Dec 160-56134430 Sep 160-77117130 Jun 160-6595931 Mar 163-5184831 Dec 153-4354030 Sep 153-640質の高い収益: 272は現在利益が出ていません。利益率の向上: 272は現在利益が出ていません。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: 272は利益が出ておらず、過去 5 年間で損失は年間18.5%の割合で増加しています。成長の加速: 272の過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。収益対業界: 272は利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( 1.2% ) と比較することは困難です。株主資本利益率高いROE: 272は現在利益が出ていないため、自己資本利益率 ( -146.07% ) はマイナスです。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/31 07:36終値2026/07/31 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Mabion S.A. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。7 アナリスト機関Beata Szparaga-WasniewskaBiuro maklerskie mBankuKamil KliszczBiuro maklerskie mBankuPawel PuchalskiErste Bank Polska S.A.4 その他のアナリストを表示
Reported Earnings • May 24First quarter 2026 earnings released: zł0.60 loss per share (vs zł0.94 loss in 1Q 2025)First quarter 2026 results: zł0.60 loss per share (improved from zł0.94 loss in 1Q 2025). Revenue: zł4.57m (up 68% from 1Q 2025). Net loss: zł9.74m (loss narrowed 36% from 1Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 81 percentage points per year, which is a significant difference in performance.
お知らせ • Aug 25Mabion S.A. to Report First Half, 2025 Results on Sep 30, 2025Mabion S.A. announced that they will report first half, 2025 results on Sep 30, 2025
Reported Earnings • Oct 29Third quarter 2024 earnings released: zł1.01 loss per share (vs zł0.67 profit in 3Q 2023)Third quarter 2024 results: zł1.01 loss per share (down from zł0.67 profit in 3Q 2023). Revenue: zł516.0k (down 98% from 3Q 2023). Net loss: zł16.3m (down 250% from profit in 3Q 2023). Revenue is expected to decline by 11% p.a. on average during the next 3 years, while revenues in the Biotechs industry in Europe are expected to grow by 21%. Over the last 3 years on average, earnings per share has increased by 43% per year but the company’s share price has fallen by 42% per year, which means it is significantly lagging earnings.
Reported Earnings • Sep 11Second quarter 2024 earnings releasedSecond quarter 2024 results: Revenue: zł29.8m (down 17% from 2Q 2023). Net income: zł10.3m (down 33% from 2Q 2023). Profit margin: 35% (down from 42% in 2Q 2023). Revenue is expected to decline by 4.2% p.a. on average during the next 3 years, while revenues in the Biotechs industry in Europe are expected to grow by 20%. Over the last 3 years on average, earnings per share has increased by 85% per year but the company’s share price has fallen by 35% per year, which means it is significantly lagging earnings.
Reported Earnings • May 19First quarter 2024 earnings released: EPS: zł1.06 (vs zł1.02 in 1Q 2023)First quarter 2024 results: EPS: zł1.06 (up from zł1.02 in 1Q 2023). Revenue: zł34.0m (down 14% from 1Q 2023). Net income: zł17.5m (up 6.5% from 1Q 2023). Profit margin: 52% (up from 42% in 1Q 2023). Revenue is forecast to grow 4.4% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has increased by 91% per year but the company’s share price has fallen by 27% per year, which means it is significantly lagging earnings.
Reported Earnings • Apr 18Full year 2023 earnings released: EPS: zł2.55 (vs zł1.44 in FY 2022)Full year 2023 results: EPS: zł2.55 (up from zł1.44 in FY 2022). Revenue: zł151.7m (down 7.5% from FY 2022). Net income: zł41.3m (up 78% from FY 2022). Profit margin: 27% (up from 14% in FY 2022). The increase in margin was driven by lower expenses. Revenue is expected to decline by 1.1% p.a. on average during the next 3 years, while revenues in the Biotechs industry in Europe are expected to grow by 18%. Over the last 3 years on average, earnings per share has increased by 103% per year but the company’s share price has fallen by 36% per year, which means it is significantly lagging earnings.
Reported Earnings • May 24First quarter 2026 earnings released: zł0.60 loss per share (vs zł0.94 loss in 1Q 2025)First quarter 2026 results: zł0.60 loss per share (improved from zł0.94 loss in 1Q 2025). Revenue: zł4.57m (up 68% from 1Q 2025). Net loss: zł9.74m (loss narrowed 36% from 1Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 81 percentage points per year, which is a significant difference in performance.
お知らせ • Aug 25Mabion S.A. to Report First Half, 2025 Results on Sep 30, 2025Mabion S.A. announced that they will report first half, 2025 results on Sep 30, 2025
お知らせ • Apr 25Mabion S.A., Annual General Meeting, May 26, 2025Mabion S.A., Annual General Meeting, May 26, 2025.
Valuation Update With 7 Day Price Move • Nov 05Investor sentiment deteriorates as stock falls 27%After last week's 27% share price decline to €2.55, the stock trades at a trailing P/E ratio of 18.9x. Average trailing P/E is 24x in the Biotechs industry in Europe. Total loss to shareholders of 84% over the past three years.
Reported Earnings • Oct 29Third quarter 2024 earnings released: zł1.01 loss per share (vs zł0.67 profit in 3Q 2023)Third quarter 2024 results: zł1.01 loss per share (down from zł0.67 profit in 3Q 2023). Revenue: zł516.0k (down 98% from 3Q 2023). Net loss: zł16.3m (down 250% from profit in 3Q 2023). Revenue is expected to decline by 11% p.a. on average during the next 3 years, while revenues in the Biotechs industry in Europe are expected to grow by 21%. Over the last 3 years on average, earnings per share has increased by 43% per year but the company’s share price has fallen by 42% per year, which means it is significantly lagging earnings.
Reported Earnings • Sep 11Second quarter 2024 earnings releasedSecond quarter 2024 results: Revenue: zł29.8m (down 17% from 2Q 2023). Net income: zł10.3m (down 33% from 2Q 2023). Profit margin: 35% (down from 42% in 2Q 2023). Revenue is expected to decline by 4.2% p.a. on average during the next 3 years, while revenues in the Biotechs industry in Europe are expected to grow by 20%. Over the last 3 years on average, earnings per share has increased by 85% per year but the company’s share price has fallen by 35% per year, which means it is significantly lagging earnings.
New Risk • Sep 03New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 100% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 100% per year for the foreseeable future. High level of non-cash earnings (128% accrual ratio). Minor Risk Market cap is less than US$100m (€71.8m market cap, or US$79.2m).
New Risk • Jul 16New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 112% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 112% per year for the foreseeable future. High level of non-cash earnings (128% accrual ratio). Minor Risk Market cap is less than US$100m (€66.5m market cap, or US$72.4m).
お知らせ • May 25Mabion S.A., Annual General Meeting, Jun 17, 2024Mabion S.A., Annual General Meeting, Jun 17, 2024.
Reported Earnings • May 19First quarter 2024 earnings released: EPS: zł1.06 (vs zł1.02 in 1Q 2023)First quarter 2024 results: EPS: zł1.06 (up from zł1.02 in 1Q 2023). Revenue: zł34.0m (down 14% from 1Q 2023). Net income: zł17.5m (up 6.5% from 1Q 2023). Profit margin: 52% (up from 42% in 1Q 2023). Revenue is forecast to grow 4.4% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has increased by 91% per year but the company’s share price has fallen by 27% per year, which means it is significantly lagging earnings.
Valuation Update With 7 Day Price Move • May 14Investor sentiment improves as stock rises 15%After last week's 15% share price gain to €4.28, the stock trades at a trailing P/E ratio of 7.1x. Average trailing P/E is 31x in the Biotechs industry in Europe. Total loss to shareholders of 57% over the past three years.
Reported Earnings • Apr 18Full year 2023 earnings released: EPS: zł2.55 (vs zł1.44 in FY 2022)Full year 2023 results: EPS: zł2.55 (up from zł1.44 in FY 2022). Revenue: zł151.7m (down 7.5% from FY 2022). Net income: zł41.3m (up 78% from FY 2022). Profit margin: 27% (up from 14% in FY 2022). The increase in margin was driven by lower expenses. Revenue is expected to decline by 1.1% p.a. on average during the next 3 years, while revenues in the Biotechs industry in Europe are expected to grow by 18%. Over the last 3 years on average, earnings per share has increased by 103% per year but the company’s share price has fallen by 36% per year, which means it is significantly lagging earnings.
お知らせ • Jan 12+ 3 more updatesMabion S.A. to Report Q3, 2024 Results on Nov 25, 2024Mabion S.A. announced that they will report Q3, 2024 results on Nov 25, 2024
New Risk • Dec 04New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 8.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 28% per year for the foreseeable future. High level of non-cash earnings (34% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (8.3% average weekly change). Market cap is less than US$100m (€84.4m market cap, or US$91.3m).
Valuation Update With 7 Day Price Move • Nov 29Investor sentiment improves as stock rises 22%After last week's 22% share price gain to €4.80, the stock trades at a forward P/E ratio of 17x. Average forward P/E is 25x in the Biotechs industry in Europe. Total returns to shareholders of 7.0% over the past year.
New Risk • Nov 17New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 34% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 18% per year for the foreseeable future. High level of non-cash earnings (34% accrual ratio). Minor Risk Market cap is less than US$100m (€65.7m market cap, or US$71.2m).
Reported Earnings • Sep 14Second quarter 2023 earnings releasedSecond quarter 2023 results: Revenue: zł36.0m (down 18% from 2Q 2022). Net income: zł15.2m (up 198% from 2Q 2022). Profit margin: 42% (up from 12% in 2Q 2022). The increase in margin was driven by lower expenses. Revenue is forecast to grow 7.4% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in Germany.
お知らせ • Jun 13Mabion S.A., Annual General Meeting, Jun 13, 2023Mabion S.A., Annual General Meeting, Jun 13, 2023, at 14:00 Central European Standard Time.
お知らせ • Jan 26+ 3 more updatesMabion S.A. to Report Fiscal Year 2022 Results on Apr 25, 2023Mabion S.A. announced that they will report fiscal year 2022 results at 5:30 PM, Central European Standard Time on Apr 25, 2023
Valuation Update With 7 Day Price Move • Aug 11Investor sentiment deteriorated over the past weekAfter last week's 21% share price decline to €5.64, the stock trades at a trailing P/E ratio of 16.1x. Average forward P/E is 25x in the Biotechs industry in Europe. Total loss to shareholders of 62% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €2.51 per share.
Valuation Update With 7 Day Price Move • Jul 18Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to €6.22, the stock trades at a trailing P/E ratio of 18.2x. Average forward P/E is 30x in the Biotechs industry in Europe. Total loss to shareholders of 50% over the past year.
Valuation Update With 7 Day Price Move • Jul 02Investor sentiment improved over the past weekAfter last week's 16% share price gain to €5.28, the stock trades at a trailing P/E ratio of 15x. Average forward P/E is 32x in the Biotechs industry in Europe. Total loss to shareholders of 64% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €2.41 per share.
Valuation Update With 7 Day Price Move • Jun 15Investor sentiment deteriorated over the past weekAfter last week's 27% share price decline to €4.51, the stock trades at a trailing P/E ratio of 12.7x. Average forward P/E is 31x in the Biotechs industry in Europe. Total loss to shareholders of 74% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €2.47 per share.
お知らせ • May 27Mabion S.A., Annual General Meeting, Jun 21, 2022Mabion S.A., Annual General Meeting, Jun 21, 2022, at 11:00 Central European Standard Time.
Breakeven Date Change • Apr 27Forecast breakeven date moved forward to 2022The analyst covering Mabion previously expected the company to break even in 2023. New forecast suggests the company will make a profit of zł59.0m in 2022. Average annual earnings growth of 69% is required to achieve expected profit on schedule.
Breakeven Date Change • Jul 27Forecast breakeven moved forward to 2022The 2 analysts covering Mabion previously expected the company to break even in 2023. New consensus forecast suggests the company will make a profit of zł59.0m in 2022. Average annual earnings growth of 63% is required to achieve expected profit on schedule.